EXTON, Pa.--3-Dimensional Pharmaceuticals and DuPont Pharmaceuticals have formed a collaboration through which 3DP will use its DirectedDi-versity technology to assist DuPont in the discovery of new drugs for specific biological targets. 3DP will apply its iterative drug discovery process to generate custom combinatorial chemistry libraries based on molecules and information provided by DuPont and will optimize those molecules into preclinical drug candidates. For the initial target, 3DP will receive payments of up to $9 million, including an up-front technology access fee, research and development funding, and milestone payments. DuPont will also take a nonexclusive license to 3DP’s Directed Discovery drug discovery patents.
In other news, 3DP received a patent for its ThermoFluor technology, a method of obtaining quantitative measurements of drug-binding affinity to almost any protein or nucleic acid target.